Antares Pharma Inc (ATRS)

Overview

Antares Pharma, Inc. operates as a specialized pharmaceutical enterprise, focusing on the innovation and marketing of medicines and advanced technologies. The company's core mission is to address critical patient needs across several therapeutic areas. This is accomplished through the development, manufacturing, and commercialization of groundbreaking therapeutic products, largely centered around distinctive drug delivery systems. A significant portion of Antares's portfolio comprises injectable solutions, addressing various medical conditions with innovative approaches.

Products and Services

• XYOSTED:

  This subcutaneous therapy is designed for testosterone replacement in adult men, addressing hormone deficiencies with an innovative delivery method.

• OTREXUP:

  A unique injectable methotrexate formulation used in the management of severe active rheumatoid arthritis, juvenile idiopathic arthritis in children, and severe recalcitrant psoriasis in adults.

• NOCDURNA:

  Sublingual tablets prescribed for adults suffering from nocturia, a condition that forces them to awaken multiple times during the night to urinate due to nocturnal polyuria.

• Epinephrine Injection USP:

  This generic epinephrine injection is critical for the urgent treatment of severe allergic reactions, including anaphylaxis, applicable for both adults and certain pediatric patients.

• Sumatriptan Injection USP:

  Utilized for the acute management of migraine and cluster headaches in adults, this product offers rapid relief for those suffering from debilitating headache disorders.

• Makena Subcutaneous Auto-Injector:

  This auto-injector is designed to lower the risk of preterm birth in women, providing a convenient delivery mechanism for essential medication.

• Teriparatide Injection:

  A treatment option for osteoporosis targeting both postmenopausal women and men at elevated fracture risk, as well as patients experiencing glucocorticoid-induced osteoporosis.

• Drug Delivery Devices:

  Antares Pharma is actively advancing various drug delivery devices, including disposable pen injectors for diabetes and osteoporosis, along with QuickShot auto-injectors that enhance the user experience for medication administration.

• TLANDO:

  Currently in development, TLANDO aims to treat testosterone deficiency in adult males, signifying Antares's commitment to expanding its therapeutic offerings in hormone replacement.

• Innovative Drug/Device Combinations:

  The company explores solutions targeting urologic oncology, immunology, and endocrinology, showcasing its dedication to tackling a diverse range of health challenges.